Salarius Pharmaceuticals Reports Shareholder Vote Matters
Ticker: DCOY · Form: 8-K · Filed: Jul 8, 2025 · CIK: 1615219
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Salarius Pharma filed an 8-K on July 8, 2025, for shareholder vote matters.
AI Summary
Salarius Pharmaceuticals, Inc. filed an 8-K on July 8, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's corporate actions and decisions requiring shareholder approval, as of the reporting date.
Why It Matters
This filing indicates that Salarius Pharmaceuticals held a shareholder meeting or is seeking shareholder approval for significant corporate actions, which could impact the company's direction and shareholder rights.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of matters submitted to a vote of security holders, not an event that inherently introduces new financial or operational risk.
Key Players & Entities
- Salarius Pharmaceuticals, Inc. (company) — Registrant
- July 8, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 2450 Holcombe Blvd. Suite X Houston, TX 77021 (address) — Principal Executive Offices
- 713-913-5608 (phone_number) — Registrant's telephone number
FAQ
What specific matters were submitted to a vote of Salarius Pharmaceuticals' security holders?
The filing indicates that matters were submitted to a vote, but the specific details of these matters are not provided in the excerpt. A full review of the 8-K document would be required to ascertain the exact proposals.
When was the report filed with the SEC?
The report was filed as of July 8, 2025.
What is the company's principal executive office address?
The principal executive offices are located at 2450 Holcombe Blvd. Suite X Houston, TX 77021.
What is the company's IRS Employer Identification Number?
The IRS Employer Identification Number is 46-5087339.
What is the SEC file number for Salarius Pharmaceuticals?
The SEC file number is 001-36812.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 8, 2025 regarding Salarius Pharmaceuticals, Inc. (DCOY).